427 related articles for article (PubMed ID: 15007102)
21. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
Römermann K; Helmer R; Löscher W
Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
[TBL] [Abstract][Full Text] [Related]
22. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
[TBL] [Abstract][Full Text] [Related]
23. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
25. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
[TBL] [Abstract][Full Text] [Related]
27. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
Matsson P; Englund G; Ahlin G; Bergström CA; Norinder U; Artursson P
J Pharmacol Exp Ther; 2007 Oct; 323(1):19-30. PubMed ID: 17616561
[TBL] [Abstract][Full Text] [Related]
28. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
Fukuda Y; Takenaka K; Sparreboom A; Cheepala SB; Wu CP; Ekins S; Ambudkar SV; Schuetz JD
Mol Pharmacol; 2013 Sep; 84(3):361-71. PubMed ID: 23775562
[TBL] [Abstract][Full Text] [Related]
29. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues.
Han Y; Riwanto M; Go ML; Ee PL
Eur J Pharm Sci; 2008 Sep; 35(1-2):30-41. PubMed ID: 18598762
[TBL] [Abstract][Full Text] [Related]
30. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
[TBL] [Abstract][Full Text] [Related]
31. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
Dupuis ML; Flego M; Molinari A; Cianfriglia M
HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546
[TBL] [Abstract][Full Text] [Related]
32. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
33. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
Gupta A; Unadkat JD; Mao Q
J Pharm Sci; 2007 Dec; 96(12):3226-35. PubMed ID: 17518356
[TBL] [Abstract][Full Text] [Related]
34. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
35. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
36. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
[TBL] [Abstract][Full Text] [Related]
38. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
[TBL] [Abstract][Full Text] [Related]
39. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
40. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
